Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Editas Medicine (EDIT) Return on Sales (2016 - 2025)

Historic Return on Sales for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to 3.33%.

  • Editas Medicine's Return on Sales rose 10152900.0% to 3.33% in Q3 2025 from the same period last year, while for Sep 2025 it was 4.26%, marking a year-over-year decrease of 8500.0%. This contributed to the annual value of 7.34% for FY2024, which is 54000.0% down from last year.
  • Latest data reveals that Editas Medicine reported Return on Sales of 3.33% as of Q3 2025, which was up 10152900.0% from 14.39% recorded in Q2 2025.
  • Editas Medicine's 5-year Return on Sales high stood at 0.31% for Q4 2023, and its period low was 1326.83% during Q3 2022.
  • Its 5-year average for Return on Sales is 146.53%, with a median of 8.73% in 2021.
  • As far as peak fluctuations go, Editas Medicine's Return on Sales tumbled by -13205200bps in 2022, and later soared by 13184000bps in 2023.
  • Editas Medicine's Return on Sales (Quarter) stood at 3.32% in 2021, then tumbled by -180bps to 9.29% in 2022, then skyrocketed by 97bps to 0.31% in 2023, then crashed by -372bps to 1.48% in 2024, then plummeted by -124bps to 3.33% in 2025.
  • Its Return on Sales was 3.33% in Q3 2025, compared to 14.39% in Q2 2025 and 16.24% in Q1 2025.